DrugPatentWatch Database Preview
Drugs in Development Information for TAK-438
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug TAK-438?
TAK-438 is an investigational drug.
There have been 322 clinical trials for TAK-438.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are sixteen US patents protecting this investigational drug and one hundred and thirty-five international patents.
Summary for TAK-438
| US Patents | 16 |
| International Patents | 135 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2018-01-01) |
| Vendors | 45 |
Recent Clinical Trials for TAK-438
| Title | Sponsor | Phase |
|---|---|---|
| A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic Hypersomnia | Millennium Pharmaceuticals, Inc. | Phase 1 |
| A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C] TAK-831 in Male Healthy Participants | Takeda | Phase 1 |
| A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection | Takeda | Phase 3 |
Clinical Trial Summary for TAK-438
Top disease conditions for TAK-438
Top clinical trial sponsors for TAK-438
US Patents for TAK-438
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-438 | Start Trial | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | Takeda Pharmaceutical Company Limited (Osaka-Shi, JP) | Start Trial |
| TAK-438 | Start Trial | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-438 | Start Trial | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP) | Start Trial |
| TAK-438 | Start Trial | Acid secretion inhibitor | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-438 | Start Trial | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-438
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-438 | China | 102421753 | 2029-02-25 | Start Trial |
| TAK-438 | China | 104211618 | 2029-02-25 | Start Trial |
| TAK-438 | China | 105524046 | 2029-02-25 | Start Trial |
| TAK-438 | China | 108129374 | 2029-02-25 | Start Trial |
| TAK-438 | European Patent Office | 2402313 | 2029-02-25 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
